Erasca Shares Fall 12% on Proposed $500 Million Stock Offering

Shares of Erasca, Inc. (NASDAQ:ERAS) fell sharply in after-hours trading Monday after the clinical-stage oncology company announced plans for a proposed public offering of $500 million of its common stock.

Offering Details

In a statement, Erasca confirmed its intent to sell the shares in an underwritten public offering, though it is subject to market and other conditions. The company also plans to grant the underwriters a 30-day option to purchase up to an additional $75 million worth of shares.

The proposed offering is being managed by a group of joint book-running managers including J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI. Erasca noted there is no guarantee as to whether or when the offering will be completed, nor about its final size or terms.

Market Reaction and Dilution

Ad

Following the news, Erasca's stock tumbled 12% in extended trading. Such a reaction is common when companies announce secondary offerings, as the issuance of new shares can dilute the value and ownership percentage of existing shareholders. This potential for dilution often puts immediate downward pressure on a company's stock price.

Use of Capital

Erasca intends to use the net proceeds, combined with its existing cash, cash equivalents, and marketable securities, to advance its clinical pipeline. The funds are earmarked for research and development of its product candidates, which target RAS/MAPK pathway-driven cancers, as well as for general working capital.